Exact Sciences builds out cancer diagnostics. Operations and Nasdaq listing shape the story

Exact Sciences Corp. (ISIN US30063P1057) is a US-based molecular diagnostics company that focuses on cancer screening and diagnostic tests, with its shares listed on Nasdaq in New York. The company’s operations, revenue base, and product portfolio give investors a clearer view of how it aims to grow within the US healthcare and diagnostics landscape.

Expanding the diagnostics footprint

Exact Sciences has built its business around laboratory-developed tests that help detect cancer or precancerous conditions using patient samples such as stool, blood, or tissue. These tests are processed in centralized laboratories, and the company then provides results back to physicians and healthcare providers who integrate the data into patient care decisions.

The company’s operations involve both significant laboratory capacity and a sizable commercial organization that markets test offerings to gastroenterologists, primary care physicians, oncologists, and health systems. This combination of lab infrastructure and field sales teams is designed to support broad adoption of its tests across the US, where early detection of cancer has become a major public health and payer priority.

Business model and revenue drivers

Exact Sciences typically generates revenue by selling its diagnostic tests to healthcare providers, who order them for eligible patients based on screening guidelines and clinical judgment. Payments are often received through a mix of private insurers, government programs, and patient self-pay, depending on coverage decisions and benefit design. Over time, expanded guideline inclusion and broader reimbursement can increase test volume and revenue.

The company also invests heavily in clinical studies that support the clinical utility and accuracy of its tests. These studies can underpin guideline recommendations and payer coverage decisions, which are key long-term drivers of demand. As additional indications or patient populations are validated, the potential addressable market for each test can widen, supporting growth in test orders and recurring revenues.

Flagship colorectal cancer test

A core element of Exact Sciences’ business model is its flagship colorectal cancer screening test, which uses stool-based DNA analysis to detect potential signs of cancer or precancerous polyps. The test is typically prescribed for average-risk adults who may be unwilling or unable to undergo colonoscopy or who prefer a noninvasive option that can be completed at home.

The test involves a kit shipped to the patient, with clear instructions for sample collection and return to a designated laboratory. Once the sample arrives at the lab, Exact Sciences runs a standardized series of assays to detect DNA markers and other signals associated with colorectal cancer. The results are then provided back to the ordering physician, who uses them to guide follow-up care, such as scheduling colonoscopy or repeating screening at a later interval.

Stock listing and investor perspective

Exact Sciences trades on Nasdaq in the US, giving the company access to a broad base of institutional and retail investors who follow healthcare and diagnostics stocks. Nasdaq listing typically supports liquidity in trading and places the company within major US stock indices and sector baskets that focus on biotechnology, life sciences tools, and medical diagnostics.

For investors, the company’s long-term value proposition frequently centers on how many patients its tests can reach, how durable reimbursement and guideline support prove to be, and how effectively Exact Sciences can manage its laboratory operations and research spending. As the market for cancer screening and diagnostics evolves, the company’s mix of established tests and pipeline programs is likely to remain a focal point for market participants and healthcare stakeholders.